^

Association details:

Biomarker:
No biomarker
Direction:
Sensitive

Evidence:

Evidence Level:
Sensitive: A1 - Approval
Title:
Merck’s KEYTRUDA (pembrolizumab) Approved in Japan for Use in the Treatment of Patients with Urothelial Carcinoma That is Unresectable with Radical Surgery Who Have Progressed Following Cancer Chemotherapy
Published date:
01/02/2018
Excerpt:
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/17/2015
Excerpt:
Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
Source:
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Published date:
04/28/2021
Excerpt:
CONTRADICTORY EVIDENCE: Pembrolizumab is not recommended, within its marketing authorisation, for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Excerpt:
...the NCCN panel recommends pembrolizumab, atezolizumab, nivolumab, durvalumab, avelumab, or erdafitinib as preffered second-line systemic therapy options after platinum-based therapy.
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our